Annovis Bio (ANVS) Enterprise Value (2019 - 2026)
Annovis Bio (ANVS) posted Enterprise Value of -$14.2 million for Q1 2026, up 27.3% sequentially from -$19.5 million in Q4 2025, and up 36.14% YoY from -$10.4 million in Q1 2025.
Annovis Bio (ANVS) Enterprise Value (2019 - 2026) Analysis & Trends
Annovis Bio has reported Enterprise Value for 8 years, with the latest figure at -$14.2 million in Q1 2026.
- Quarterly Enterprise Value rose 36.14% year-over-year to -$14.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$14.2 million (up 36.14% YoY) and the FY2025 annual result came in at -$19.5 million, down 85.11% from the prior year.
- Enterprise Value advanced to -$14.2 million in Q1 2026 per ANVS's latest filing, from -$19.5 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$3.1 million in Q1 2024 and troughed at -$42.7 million in Q1 2022.
- A 5-year average of -$17.6 million and a median of -$15.7 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2023: Enterprise Value sank 661.56% in 2022, then soared 87.89% in 2023.
- Over 5 years, Enterprise Value stood at -$28.4 million in 2022, then jumped by 79.72% to -$5.8 million in 2023, then tumbled by 83.36% to -$10.6 million in 2024, then slumped by 85.11% to -$19.5 million in 2025, then climbed by 27.3% to -$14.2 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$14.2 million, -$19.5 million, and -$15.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.90 Bn | 131.05 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 86.10 Bn | 78.11 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.37 Bn | 1.37 Bn | -5.18 Bn |
| 4 | Moderna | 55.82 Bn | 50.68 Bn | 52.00 Mn | -5.14 Bn |
| 5 | BeOne Medicines | 42.14 Bn | 37.04 Bn | 1.53 Bn | -5.10 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | -3.31 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | -18.39 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | -1.16 Bn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 2.12 Bn |
| 10 | Annovis Bio | 66.97 Mn | 66.97 Mn | - | -18.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.20 Mn |
| Dec 31, 2025 | -19.53 Mn |
| Sep 30, 2025 | -15.30 Mn |
| Jun 30, 2025 | -17.10 Mn |
| Mar 31, 2025 | -22.24 Mn |
| Dec 31, 2024 | -10.55 Mn |
| Sep 30, 2024 | -12.64 Mn |
| Jun 30, 2024 | -4.00 Mn |
| Mar 31, 2024 | -3.10 Mn |
| Dec 31, 2023 | -5.75 Mn |
| Sep 30, 2023 | -3.87 Mn |
| Jun 30, 2023 | -15.72 Mn |
| Mar 31, 2023 | -16.53 Mn |
| Dec 31, 2022 | -28.38 Mn |
| Sep 30, 2022 | -31.99 Mn |
| Jun 30, 2022 | -35.97 Mn |
| Mar 31, 2022 | -42.67 Mn |
| Dec 31, 2021 | -45.69 Mn |
| Sep 30, 2021 | -47.46 Mn |
| Jun 30, 2021 | -49.22 Mn |